OCTREOTIDE ACETATE OMEGA 200 MCG — DIN 02248642
OCTREOTIDE (OCTREOTIDE ACETATE) : 200 MCG · OMEGA LABORATORIES LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is OCTREOTIDE ACETATE OMEGA?
OCTREOTIDE ACETATE OMEGA 200 MCG contains OCTREOTIDE (OCTREOTIDE ACETATE) : 200 MCG. It is listed in the Health Canada Drug Product Database under DIN 02248642, held by OMEGA LABORATORIES LIMITED, supplied as SOLUTION for SUBCUTANEOUS ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 11-Mar-2004. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OCTREOTIDE ACETATE OMEGA used for?
Control of symptoms in metastatic carcinoid, VIPomas, and acromegaly; prevention of complications following pancreatic surgery; emergency management of bleeding gastro-oesophageal varices.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Octreotide cost around the world?
Octreotide is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 6 | 30 | AUD███.██ |
| Italy | prezzo al pubblico (classe A) | 20 | 20 | EUR███.██ |
| Greece | producer price (ex-factory) | 8 | 8 | EUR███.██ |
| South Africa | single exit price | 7 | 8 | ZAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 6 | 6 | EUR███.██ |
| United Kingdom | hospital | 6 | 6 | GBP███.██ |
| United States | acquisition | 1 | 4 | USD███.██ |
| Bahrain | retail (max) | 2 | 3 | BHD███.██ |
| Luxembourg | reimbursement | 3 | 3 | EUR███.██ |
| Morocco | PPV (public price) | 1 | 3 | MAD███.██ |
| Czechia | max producer price (ex-factory) | 1 | 2 | CZK███.██ |
93 pack listings across 61 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Octreotide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Octreotide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Octreotide, across 33 DINs, of which 9 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| OMEGA LABORATORIES LIMITED | 4 | 4 | OCTREOTIDE ACETATE OMEGA | Sourceable in Canada |
| STERIMAX INC | 3 | 3 | OCTREOTIDE INJECTION | Sourceable in Canada |
| NOVARTIS PHARMACEUTICALS CANADA INC | 5 | 2 | SANDOSTATIN, SANDOSTATIN LAR | Sourceable in Canada |
| TEVA CANADA LIMITED | 7 | 0 | OCTREOTIDE FOR INJECTABLE SUSPENSION, OCTREOTIDE INJECTION | No marketed DIN |
| MONT-PHARMA INC | 4 | 0 | OCTREOTIDE INJECTION | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 4 | 0 | OCTREOTIDE ACETATE INJECTION - 100MCG/ML, OCTREOTIDE ACETATE INJECTION - 200MCG/ML, OCTREOTIDE ACETATE INJECTION - 500MCG/ML, OCTREOTIDE ACETATE INJECTION - 50MCG/ML | No marketed DIN |
| GENERIC MEDICAL PARTNERS INC | 3 | 0 | OCTREOTIDE ACETATE INJECTION | No marketed DIN |
| PENDOPHARM DIVISION OF PHARMASCIENCE INC | 3 | 0 | OCPHYL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MCG |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS ; INTRAVENOUS |
| Pack configuration (monograph) | Single dose 2-mL vials (50, 100, or 500 mcg/mL) in boxes of 5. Multidose 5-mL vials (200 mcg/mL) in boxes of 1. |
| Storage | Diluted solution in physiological saline is stable for 24 hours when stored at room temperature. (Note: Specific refrigerated storage for vials not explicitly in text). |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Octreotide |
|---|---|
| ATC code | H01CB02 |
| AHFS class | 92:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02248642 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2248642 |
| Brand name | OCTREOTIDE ACETATE OMEGA |
| Generic / active ingredient | OCTREOTIDE (OCTREOTIDE ACETATE) : 200 MCG |
| Market authorization holder | OMEGA LABORATORIES LIMITED |
| Health Canada schedule | Prescription |
| ATC code | H01CB02 |
| ATC anatomical main group | H — Systemic hormonal preparations |
| ATC therapeutic subgroup | H01CB |
| Current status | MARKETED |
| Status date | 11-Mar-2004 |
| Original market date | 2004-03-11 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
SC (recommended) or IV. Initial: 50 mcg once/twice daily. Maintenance varies by indication (e.g., 100-600 mcg/day for Carcinoid). IV infusion: 25 mcg/hour for 48-120 hours for variceal bleeding.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.
Warnings and precautions
May cause hypoglycemia/hyperglycemia, hypothyroidism, and gallbladder stones (cholelithiasis). Monitor GH/IGF-1, thyroid function, and gallbladder via ultrasound every 6 months.
Is Octreotide in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by OMEGA LABORATORIES LIMITED, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 33 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| OCTREOTIDE ACETATE OMEGA | 50 MCG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | 02248639 |
| OCTREOTIDE ACETATE OMEGA | 100 MCG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | 02248640 |
| OCTREOTIDE ACETATE OMEGA | 500 MCG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | 02248641 |
| OCTREOTIDE INJECTION | 200 MCG | SOLUTION | STERIMAX INC | MARKETED | 02560283 |
| OCTREOTIDE INJECTION | 500 MCG | SOLUTION | STERIMAX INC | MARKETED | 02560291 |
| OCTREOTIDE INJECTION | 100 MCG | SOLUTION | STERIMAX INC | MARKETED | 02560240 |
| SANDOSTATIN | 50 MCG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 00839191 |
| SANDOSTATIN LAR | 30 MG | Powder For Suspension, Sustained-Release | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02239325 |
| OCPHYL | 100 MCG | SOLUTION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | CANCELLED POST MARKET | 02413205 |
| OCPHYL | 500 MCG | SOLUTION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | CANCELLED POST MARKET | 02413213 |
2 · Same class — other molecules in ATC H01CB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Octreotide | OCPHYL · OCTREOTIDE ACETATE INJECTION · OCTREOTIDE ACETATE INJECTION - 100MCG/ML · OCTREOTIDE ACETATE INJECTION - 200MCG/ML · +7 more | 33 | 9 | Yes |
| Pasireotide | SIGNIFOR · SIGNIFOR LAR | 8 | 8 | Yes |
| Lanreotide | MYTOLAC · SOMATULINE AUTOGEL | 6 | 6 | Yes |
| Somatostatin | STILAMIN - PWS IV 3MG/AMP · STILAMIN - PWS LIQ IV | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC H01C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| H01CC | Cetrorelix · Elagolix · Ganirelix · Relugolix, Estradiol And Norethisterone | 6 | 5 |
| H01CA | Gonadorelin · Nafarelin | 4 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is OCTREOTIDE ACETATE OMEGA called?
The same molecule, Octreotide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Sandostatin LAR | Latin | Australia, Czechia |
| Octreotide (SUN) | Latin | Australia |
| Octreotide GH | Latin | Australia |
| Sandostatin | Latin | Bahrain, South Africa |
| SANDOSTATINE * | Latin | Morocco |
| SYNGRO | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.